Accepted for Publication: April 4, 2014.
Published Online: June 16, 2014. doi:10.1001/jamaneurol.2014.999.
Study concept and design: Greene, Lai, Dalmau, Lancaster.
Acquisition, analysis, or interpretation of data: Greene, Lai, Baella, Lancaster.
Drafting of the manuscript: Greene, Lancaster.
Critical revision of the manuscript for important intellectual content: All authors.
Obtained funding: Lancaster.
Administrative, technical, or material support: Greene, Lai, Baella, Lancaster.
Study supervision: Dalmau, Lancaster.
Conflict of Interest Disclosures: Dr Dalmau has a research grant from Euroimmun and receives royalties from patents for the use of Ma2 and NMDAR as autoantibody tests. No other disclosures were reported.
Funding/Support: This study was supported by a Dana Foundation Neuroimmunology award (Dr Lancaster) and by grant K08 NS075142 from the National Institutes of Health.
Role of the Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the patients who donated their medical information and CSF and serum samples for these studies. Steven S. Scherer, MD, PhD (University of Pennsylvania), provided many useful discussions and advice regarding this project. Esther de Graaff, PhD, Peter Sillevis-Smitt, MD, PhD, and colleagues (Erasmus Medical Center, Rotterdam, the Netherlands) shared their plasmids for expressing DNER, which were originally from Mineko Kengaku, PhD, and her group (Institute for Integrated Cell-Material Sciences, Kyoto University, Japan). No financial compensation was given for these services.